New Drug Cures Some Blood Cancer Patients in Trials

Friday, 08 Nov 2013 12:59 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Geron Corp said 22 percent of trial patients treated with its experimental blood cancer drug were now free of the disease, a major break for the company after two big setbacks.
Shares of Geron more than doubled in morning trade on Thursday to a four-year high.
"This is going to save the company, because it's the last thing that they had," MLV & Co analyst George Zavoico told Reuters. "This truly opens the door for other opportunities in other indications."
Geron earlier failed to develop the blood cancer drug, imetelstat, to treat breast cancer. It also stopped working on its brain cancer drug.
Imetelstat is designed to treat myelofibrosis, a rare form of blood cancer.
Zavoico said the data validated imetelstat's "mechanism of action" and suggested it was superior to Incyte Corp's Jakafi, which is approved to treat myelofibrosis.
Imetelstat is designed to inhibit telomerase, an enzyme that enables rapid multiplication of cancer cells.
Jakafi inhibits another family of enzymes, reducing cell multiplication. The drug had sales of $136 million in 2012.
Zavoico said Jakafi reduced spleen size and relieved symptoms, but did not have a disease-modifying effect, defined as partial or complete remission.
Geron said one patient of the first 18 enrolled in the trial showed partial remission.
The company released the data ahead of a presentation on December 9 at the annual meeting of the American Society of Hematology.
 

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Comments
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Find Your Condition
You May Also Like
Around the Web
Most Commented

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

NEWSMAXHEALTH.COM
© Newsmax Media, Inc.
All Rights Reserved